Deal-making between universities and medical device companies has historically been limited. Not only are such deals often too pricey for device companies, the nature of medical device innovation--more likely to be incremental improvements than quantum leaps forward--gives physicians and entrepreneurs an edge over universities. But that may be changing, as this look at university/medical device deals in the first half of 1997 shows.
Last month in this space, we rounded up six months' worth of announced university licensing agreements in the pharmaceutical area. This month, we put together all the other license agreements between health care companies and academia—and the volume of deals doesn't even come close.
This isn't a fluke. Universities say that 80% of their dealmaking in health care is related to drug development—not least...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
